|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:approves
|
gptkb:2017
gptkb:FDA
|
|
gptkbp:clinical_trial
|
gptkb:OPERA_I
gptkb:OPERA_II
Phase III
ORATORIO
|
|
gptkbp:clinical_use
|
long-term treatment
|
|
gptkbp:contraindication
|
active infections
hypersensitivity to ocrelizumab
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:duration
|
every 6 months
|
|
gptkbp:financial_support
|
available through Genentech
|
|
gptkbp:formulation
|
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ocrevus
|
|
gptkbp:indication
|
gptkb:primary_progressive_multiple_sclerosis
gptkb:relapsing_forms_of_multiple_sclerosis
|
|
gptkbp:ingredients
|
gptkb:ocrelizumab
|
|
gptkbp:invention
|
2028
|
|
gptkbp:manufacturer
|
gptkb:Genentech
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
CD20 B-cell depletion
|
|
gptkbp:patient_population
|
adults
children over 18 years
|
|
gptkbp:pharmacokinetics
|
B-cell depletion
half-life of 26 days
|
|
gptkbp:price
|
high-cost medication
|
|
gptkbp:provides_guidance_on
|
MS treatment guidelines
|
|
gptkbp:recommissioned
|
with sterile water
|
|
gptkbp:research
|
studies on combination therapies
ongoing studies for other indications
studies on long-term effects
|
|
gptkbp:research_focus
|
neurology
autoimmune diseases
immunology
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety_measures
|
post-marketing studies
risk evaluation and mitigation strategy (REMS)
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
rash
infections
infusion reactions
hypersensitivity reactions
malignancies
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:treatment
|
improved quality of life
reduced relapse rates
slowed disability progression
|
|
gptkbp:type_of_insurance
|
varies by plan
|
|
gptkbp:used_for
|
gptkb:multiple_sclerosis
|
|
gptkbp:website
|
vein
|
|
gptkbp:bfsParent
|
gptkb:Genentech
|
|
gptkbp:bfsLayer
|
4
|